GLP-1 BMI and Eligibility Requirements: Who Actually Qualifies

The short answer

The number on the scale is only half the question. The other half is which drug you are trying to qualify for and why. Ozempic (semaglutide) and Mounjaro (tirzepatide) share the same active ingredients as Wegovy and Zepbound, but the FDA approved them for type 2 diabetes, not weight loss. Prescribing either one for weight alone is off-label, and that single distinction changes how a prescriber writes it, whether insurance will pay, and what you will be asked to document.

This page explains the exact BMI cutoffs from the labels, what a prescriber accepts as a qualifying comorbidity, how adult and pediatric eligibility differ, who is disqualified by contraindications, and why two people with the same BMI can get very different answers on cost. It also covers the interactions that matter specifically for women, including the effect tirzepatide can have on oral birth control.

The exact BMI thresholds printed on the FDA labels

For the two GLP-1-class drugs approved for chronic weight management, the FDA labels define eligibility with one number and one either/or. The Indications section states the drug is intended for adults with an initial BMI of 30 kg/m2 or greater, which the label classifies as obesity, or a BMI of 27 kg/m2 or greater, classified as overweight, when accompanied by at least one weight-related comorbid condition. Both Wegovy's and Zepbound's prescribing information use this same 30-or-27-with-a-condition framework.

BMI is weight in kilograms divided by height in meters squared. In practical terms, a BMI of 30 corresponds to roughly 174 pounds at 5'4" or 209 pounds at 5'10"; a BMI of 27 corresponds to roughly 157 pounds at 5'4" or 188 pounds at 5'10". A prescriber calculates it from your measured height and weight at the visit, not a self-reported estimate, because the recorded number becomes the clinical justification in your chart.

The label also frames these drugs as an addition to a reduced-calorie diet and increased physical activity, not a replacement for them. That wording matters for eligibility because payers frequently require documentation that lifestyle measures were tried, so the clinical rationale in the label and the paperwork a plan wants tend to line up.

What actually counts as a weight-related comorbidity

If your BMI is between 27 and 30, eligibility depends entirely on having a qualifying weight-related condition. The FDA labels name the same core examples used across the class: hypertension (high blood pressure), type 2 diabetes, and dyslipidemia (abnormal cholesterol or triglycerides). These are the conditions most consistently accepted because they are documented with objective numbers a prescriber can point to.

Beyond that core list, clinicians commonly recognize obstructive sleep apnea, cardiovascular disease, and certain other weight-driven conditions as qualifying comorbidities, and guidance from bodies such as NIDDK discusses obesity as a condition that raises the risk of these same problems. The key is that the condition is documented in your record and is plausibly weight-related, not simply mentioned in passing.

A condition you suspect but have never had diagnosed does not qualify you on paper. If you believe you have high blood pressure or prediabetes, the practical first step is getting it measured and recorded, because a BMI of 27 with an undocumented condition reads, to a payer, the same as a BMI of 27 with no condition at all.

Eligibility by drug: weight indication vs diabetes indication

The single most important eligibility fact is which drug you are asking for. Wegovy and Zepbound carry an FDA weight-management indication, so the BMI 30 / 27-plus-condition criteria apply directly. Ozempic and Mounjaro are FDA-approved for type 2 diabetes; there is no BMI cutoff for a weight-loss use because weight loss is not their approved use. Prescribing them for weight alone is off-label.

This is why two people at the same BMI can be routed to completely different products. Someone with type 2 diabetes may be prescribed Ozempic or Mounjaro on-label for glucose control, with weight loss as a welcome secondary effect. Someone without diabetes seeking weight loss is a candidate for Wegovy or Zepbound, the products whose labels actually describe their situation.

The table below summarizes the approved use and eligibility logic for each drug. Treat it as the map for which conversation to have with a prescriber, not as a coverage promise, which is a separate layer covered further down.

Why the diabetes vs weight indication changes coverage, not just labeling

Insurers write their formularies around FDA indications, so the on-label versus off-label distinction becomes a coverage distinction. A plan that covers Ozempic for a member with type 2 diabetes may exclude weight-loss drugs entirely, or cover Wegovy and Zepbound only under a separate benefit with its own rules. The drug being chemically similar does not make the benefit similar.

Because of this, prescribing a diabetes drug off-label for weight rarely helps with coverage and can create problems. If the record does not document diabetes, a claim for Ozempic used for weight can be denied, and paying cash for a diabetes drug to treat weight forgoes the on-label weight products that were designed and studied for that purpose.

The cleaner path for weight loss is to qualify for the drug whose label matches your goal. Meeting the BMI criteria for Wegovy or Zepbound gives a prescriber an on-label rationale, which is the strongest position for both the prescription itself and any coverage request that follows.

How BMI is measured — and the edge cases that trip people up

Eligibility rests on a measured BMI, so how it is captured matters. Clinics use your height and weight at the visit; a number from a home scale or an old chart entry may not match, and the visit number is what anchors the prescription. If you are near a threshold, the reading on the day decides which door is open.

BMI has known limits as a body-composition measure. Very muscular individuals can post a high BMI without excess fat, and people can carry meaningful metabolic risk at a lower BMI. The labels use BMI because it is the criterion the drugs were studied against, but a prescriber evaluates the whole picture, including where the threshold sits relative to your documented conditions.

One practical edge case: if your BMI has dropped just below 30 through prior effort but you still have a qualifying condition, the 27-with-a-comorbidity pathway may still apply. The two pathways exist precisely so that people who are overweight with a related condition are not excluded for missing the obesity cutoff by a point or two.

Pediatric vs adult eligibility

Adult eligibility uses the absolute BMI cutoffs of 30 and 27. Pediatric eligibility does not work the same way, because a fixed adult BMI number is not meaningful for a growing adolescent whose healthy range shifts with age and sex.

Wegovy's FDA label extends to adolescents aged 12 and older and, per that label, defines the pediatric threshold using BMI at or above a growth-chart percentile for age and sex rather than the adult absolute cutoffs. Families weighing this option should read the age-specific criteria directly on the label and discuss them with a pediatric clinician, because the qualifying logic, dosing, and monitoring differ from the adult path.

Not every GLP-1 product carries a pediatric weight indication, and indications can differ between drugs and change over time. The reliable way to confirm whether a specific product is approved for a specific age group is to check that product's current FDA prescribing information and the Drugs@FDA database rather than assuming the adult rules carry over.

Contraindications: who should not take these drugs regardless of BMI

Meeting the BMI criteria does not override a contraindication. The GLP-1-class labels carry a boxed warning about thyroid C-cell tumors observed in rodent studies, and the drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A qualifying BMI cannot make these drugs appropriate for someone in those groups.

The labels also list a contraindication for prior serious hypersensitivity to the active ingredient or product components. Beyond outright contraindications, the prescribing information describes warnings and precautions — such as pancreatitis, gallbladder problems, and gastrointestinal effects — that a prescriber weighs against your history before starting therapy.

This is why a legitimate prescription requires a clinical evaluation, not just a number. A prescriber screens for the boxed-warning history and other risks precisely because the drug being effective for weight does not make it safe for everyone who meets the weight criteria.

What eligibility means specifically for women's hormonal health

For women in their reproductive years, one interaction sits at the center of drug choice: tirzepatide (Zepbound and Mounjaro) can reduce the effectiveness of oral contraceptives, and its label advises additional precautions around starting and dose changes. Semaglutide (Wegovy and Ozempic) does not carry that oral-contraceptive warning. If reliable birth control on a daily pill is a priority, that difference is a genuine eligibility-and-choice factor, not a footnote.

Pregnancy is a hard stop. The weight-management GLP-1 labels advise against use in pregnancy because weight loss offers no benefit and may cause harm during pregnancy, and the drugs are generally discontinued before a planned pregnancy. Anyone who could become pregnant should factor contraception reliability and pregnancy plans into the eligibility conversation up front.

For women navigating menopause, weight questions often overlap with menopause hormone therapy. These are separate treatments with separate criteria; ACOG's patient guidance on hormone therapy addresses menopause symptoms, not weight, and hormone therapy is not a weight-loss treatment. If you are weighing menopause hormone therapy costs, our own how-much-does cost pages and ACOG are better starting points than any weight-drug price.

What eligibility means for cost — structure, not a single price

Qualifying clinically and being able to afford the drug are different questions, and the price you pay depends on which pathway you land in, not on a single sticker number. The list price set by the manufacturer is rarely what an individual pays; the meaningful figure is your out-of-pocket cost under whichever pathway applies to you. Because these figures change, the only reliable place to read a current number is the manufacturer's own coverage and savings page for that drug.

There are five distinct cost pathways, and they are not interchangeable. An insured copay applies if your plan covers the drug; a manufacturer savings card can lower cost for eligible commercially insured patients on specific terms; a cash or self-pay program is a manufacturer's direct price for people without qualifying coverage; and compounded versions sit outside all of this as non-FDA-approved products. Lilly publishes Zepbound and Mounjaro coverage and savings details on its sites, and Novo Nordisk publishes Wegovy and Ozempic savings and NovoCare cost pages; those pages hold the live terms and numbers.

The table below shows the structure so you know which question to ask. It deliberately contains no dollar figures, because a current, accurate number for your situation lives only on the manufacturer page and on your own plan's benefit summary.

Compounded GLP-1s and the eligibility and safety gap

Compounded semaglutide and tirzepatide are marketed as lower-cost alternatives, but they are not FDA-approved products. The FDA has warned about unapproved and compounded GLP-1 products, and the availability of legally compounded versions shifted as the underlying drugs moved on and off the FDA's shortage list. A price advantage does not change the approval status.

Because compounded products are not FDA-approved, they are not backed by the same manufacturing, purity, and labeling oversight as the branded drugs, and the BMI eligibility framework on the FDA labels applies to the approved products, not to compounded copies. Choosing a compounded version to sidestep cost also sidesteps the safeguards that the label and its screening are meant to provide.

If cost is the barrier, the safer route than a compounded product is to work the legitimate pathways: check the manufacturer's cash or savings program, confirm whether your plan covers the on-label product, and compare licensed providers rather than buying an unapproved copy from an unfamiliar seller.

The legal telehealth path to qualifying online

You cannot legally buy an FDA-approved GLP-1 without a prescription, and any site offering to ship one without a clinical evaluation is a red flag. The legitimate online path has the same backbone as an in-person one: an eligibility check, a consultation with a licensed prescriber who can assess your BMI, conditions, and contraindications, and dispensing through a licensed pharmacy.

A credible telehealth service collects your measured height and weight, screens for the boxed-warning history and other risks, and only then decides whether a prescription is appropriate. If a service skips the medical evaluation, promises approval regardless of your history, or sells the drug directly without a prescriber, treat that as a warning sign rather than a convenience.

Because prescribing is regulated at the state level, the practical step is to compare providers licensed in your state and confirm they use FDA-approved products dispensed by a licensed pharmacy. That is the difference between a legal prescription and an unapproved seller, and it is worth confirming before you share payment or health information.

When you qualify clinically but coverage still says no

A BMI at or above the label threshold is a clinical qualification, not a coverage guarantee. Many plans layer their own rules on top of the FDA criteria: prior authorization, documentation of prior weight-loss attempts, step therapy requiring an alternative first, or an outright exclusion of weight-loss drugs from the benefit. Meeting the label and meeting your plan's policy are two separate tests.

When a claim is denied despite a qualifying BMI, the productive response is usually documentation rather than a different drug. That means a recorded BMI, documented weight-related conditions, and a note on lifestyle measures attempted — the same evidence the label frames as the clinical rationale. An appeal supported by that record is stronger than a resubmission of the same claim.

If coverage remains unavailable, the manufacturer cash and savings pathways exist for exactly this situation, and comparing them against a licensed provider's pricing is the honest way to weigh options. What does not solve a coverage problem is switching to an off-label diabetes drug or an unapproved compounded copy to chase a lower price.

Frequently asked questions

What BMI do you need to qualify for a GLP-1 for weight loss?

The FDA weight-management labels for Wegovy and Zepbound set eligibility at a BMI of 30 or higher, or a BMI of 27 or higher when you also have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. The BMI is measured at your visit and recorded as the clinical justification.

Can you qualify with a BMI under 27?

For the FDA-approved weight-management drugs, no. The labels set the lower entry point at a BMI of 27 combined with a weight-related condition, so a BMI below 27 does not meet the label criteria for these products. A prescriber evaluates the whole clinical picture, but the labeled thresholds are the starting point.

Why can someone get Ozempic through insurance but not Wegovy?

Ozempic is FDA-approved for type 2 diabetes, so a plan may cover it for a member with a diabetes diagnosis. Wegovy is approved for weight management, which many plans cover under separate rules or exclude entirely. Insurers write coverage around FDA indications, so the diabetes-versus-weight distinction becomes a coverage distinction.

Does a family history of thyroid cancer disqualify you?

A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is a contraindication on the GLP-1-class labels, which carry a boxed warning about thyroid C-cell tumors seen in rodents. Meeting the BMI criteria does not override that contraindication; a prescriber screens for this history before prescribing.

Do GLP-1 drugs affect birth control?

Tirzepatide, the active ingredient in Zepbound and Mounjaro, can reduce the effectiveness of oral contraceptives, and its label advises additional precautions around starting and dose changes. Semaglutide, in Wegovy and Ozempic, does not carry that warning. For anyone relying on a daily contraceptive pill, that difference is worth raising with a prescriber.

Can teenagers get GLP-1 drugs for weight?

Some products extend to adolescents, but the criteria differ from adults. Wegovy's label includes adolescents aged 12 and older and defines the threshold using a BMI growth-chart percentile for age and sex rather than the adult absolute cutoffs. Confirm the age-specific criteria on the current label and discuss them with a pediatric clinician.

Is compounded semaglutide or tirzepatide FDA-approved?

No. Compounded semaglutide and tirzepatide are not FDA-approved products, and the FDA has warned about unapproved GLP-1 products. Their availability shifted with the branded drugs' shortage status. The FDA BMI eligibility framework applies to the approved products, and compounded copies lack the same manufacturing and labeling oversight.

Does meeting the BMI cutoff guarantee my insurance will pay?

No. The BMI threshold is a clinical qualification from the FDA label, but plans add their own rules — prior authorization, documentation of prior weight-loss attempts, step therapy, or exclusion of weight-loss drugs. If a claim is denied despite a qualifying BMI, a documented record supporting an appeal is usually more effective than switching drugs.

Primary sources

1. FDA Prescribing Information, Zepbound (tirzepatide) injection.
2. FDA Prescribing Information, Wegovy (semaglutide) injection.
3. FDA Prescribing Information, Mounjaro (tirzepatide) injection.
4. FDA Prescribing Information, Ozempic (semaglutide) injection.
5. FDA Drugs@FDA approved-drug database (verify a product is FDA-approved).
6. NIDDK (NIH), Prescription Medications to Treat Overweight & Obesity.
7. Lilly, Zepbound coverage & savings.
8. Novo Nordisk, Save on Wegovy.
9. NovoCare, Wegovy cost & coverage.
10. ACOG, Hormone Therapy for Menopause (patient FAQ).